APWM
CRSP icon

Atlas Private Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Atlas Private Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-133
Closed -$10K – 407
2020
Q2 		$10K Hold
133
– – 0.01% 325
2020
Q1 		$6K Hold
133
– – 0.01% 349
2019
Q4 		$8K Buy
+133
New +$7.26K 0.01% 362

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Atlas Private Wealth Management's CRSP Position: Q3 2020 in Review

Atlas Private Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 133 shares — an estimated $10K sold.

Atlas Private Wealth Management first reported a position in CRSP in Q4 2019 and held it in 3 quarters. The position peaked at $10K in Q2 2020. 310 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Atlas Private Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Atlas Private Wealth Management sold 133 CRISPR Therapeutics shares in Q3 2020, an estimated $10K.
  • Atlas Private Wealth Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 3 quarters.
  • Atlas Private Wealth Management's CRISPR Therapeutics position peaked at $10K in Q2 2020.
  • 310 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Atlas Private Wealth Management's 13F filing for Q3 2020, filed 5 Nov 2020.